Possible zoledronic acid-induced dermatomyositis.
Z
Z
Apalla
T
T
Tzellos
A
A
Lallas
E
E
Sotiriou
I
I
Lefaki
D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D003882:Dermatomyositis / Q000139:chemically induced*; D004164:Diphosphonates / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects*; D011239:Prednisolone / Q000627:therapeutic use; D016896:Treatment Outcome; D000077211:Zoledronic Acid
D000893:Anti-Inflammatory Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D011239:Prednisolone